AstraZeneca
Repare Therapeutics Shuffles Pipeline, Pauses Some Programs Pending Partnership
The firm will pause development of lunresertib and camonsertib while focusing on development of two newer programs.
NICE Recommends Lynparza for BRCA1/2-Mutant Breast Cancer
The institute originally began reviewing Lynparza in this setting in 2018 but ended its review due to lack of evidence.
Hutchmed Submits NDA in China for Orpathys, Tagrisso Combo in EGFR, MET-Driven NSCLC
The firm also announced that it was divesting most of its equity interest in Shanghai Hutchison Pharmaceuticals to invest in its own pipeline.
AstraZeneca, Daiichi Sankyo Withdraw EU Application for Dato-DXd in Nonsquamous NSCLC
The decision follows a similar one in the US and is due to the drug's failure to significantly improve overall survival versus chemo in the TROPION-Lung01 trial.
European Commission Approves AstraZeneca's Tagrisso in Unresectable EGFR-Mutated NSCLC
Tagrisso is the first targeted therapy for European patients with unresectable EGFR-mutated lung cancer.
Nov 19, 2024